The quest for effective and safe obesity treatments has yielded both successes and disappointments in the biotech industry. While some companies like Eli Lilly and Novo Nordisk have triumphed with drugs like Zepbound and Wegovy, others have faced setbacks. Terns Pharmaceuticals, for example, initially showed promise with its GLP-1 pill TERN-601, which demonstrated a 5% reduction in participants’ body weight in Phase I trials. However, Terns has now exited the obesity space entirely, shifting its focus to cancer therapeutics and seeking partners for its weight-loss assets.
The landscape of obesity drug development is fiercely competitive, with the market projected to reach $150 billion by 2035. Many companies have encountered challenges in bringing their obesity drugs to market, grappling with safety issues and struggling to differentiate their products in a crowded field. This article delves into five molecules that were once hailed as potential game-changers in the obesity arena but ultimately failed to meet expectations.
Pfizer’s danuglipron, a GLP-1 pill, was initially positioned as a frontrunner in the obesity race, touted for its potential efficacy. However, the drug faced hurdles, including high rates of side effects such as nausea, leading to patient dropouts. Despite attempts to pivot to a once-daily regimen, safety concerns ultimately led Pfizer to discontinue danuglipron. Similarly, Roche’s CT-173, acquired from Carmot Therapeutics, failed to meet the company’s development criteria and was abandoned, highlighting the challenges of navigating the competitive obesity landscape.
Amgen’s AMG 786, a lesser-known candidate in its obesity portfolio, was cut early in the drug development process. The pharma redirected its focus to MariTide, a promising bispecific molecule targeting the GLP-1 receptor and GIP pathway. While Amgen’s decision to prioritize MariTide may have impacted its stock performance, the company remains committed to advancing this innovative asset through clinical trials. On the other hand, BioAge Labs experienced setbacks with azelaprag, leading to the discontinuation of its Phase II trial due to safety concerns. Despite this setback, BioAge is exploring novel approaches to combat obesity by targeting NLRP3 signaling with its lead asset, BGE-102.
Boehringer Ingelheim’s collaboration with Zealand Pharma yielded mixed results, with the termination of BI 1820237 due to high rates of gastrointestinal side effects. However, the company’s focus on survodutide, a GLP-1/GCCR dual agonist, shows promise in late-stage development for obesity and related conditions. By examining these failed obesity assets, the biotech industry gains valuable insights into the challenges of drug development in this complex therapeutic area.
Key Takeaways:
– Developing effective obesity treatments presents significant challenges, including safety concerns and market differentiation.
– Companies like Pfizer, Roche, Amgen, BioAge Labs, and Boehringer Ingelheim have faced setbacks in their obesity drug development efforts.
– Prioritizing innovative drug candidates with strong safety profiles is crucial for success in the competitive obesity market.
– Despite failures, companies continue to explore new avenues for obesity treatment, highlighting the resilience and adaptability of the biotech industry.
Tags: clinical trials, biotech
Read more on biospace.com